Aspen Aerogels, Inc. — Q3 2014 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2014. Unaudited consolidated financial statements; amounts below are in millions of dollars unless stated otherwise.
Business context and reporting period
Aspen designs and manufactures aerogel insulation products and performs contract research services. Its products primarily serve energy infrastructure markets. Product revenue accounted for 97% of revenue in both Q3 and the first nine months of 2014. The filing reports completion of the company’s IPO in June 2014.
Financial performance and liquidity
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Total revenue | $25.4 | $21.9 | $74.4 | $61.9 |
| Gross profit (margin) | $5.1 (20%) | $3.6 (16%) | $11.8 (16%) | $7.2 (12%) |
| Operating loss | $(2.4) | $(4.7) | $(13.4) | $(13.3) |
| Net loss | $(2.4) | $(12.7) | $(63.6) | $(30.7) |
| Adjusted EBITDA (non-GAAP) | $1.2 | $0.7 | $1.7 | $(2.0) |
- Q3 product shipments rose 6% to 9.4 million square feet; the nine-month total rose 13% to 28.2 million square feet. Average selling price increased 11% in Q3 to $2.63 per square foot and 9% year to date to $2.55.
- For the nine months, operating cash flow was $1.9, versus cash use of $14.0 in 2013. Investing activities used $4.6, primarily for capital expenditures. Financing activities provided $54.8, including IPO proceeds.
- At September 30, cash was $53.7; current assets were $81.1 and current liabilities $21.0. Total debt obligations were approximately $0.2 of capital leases. The company had no revolving-credit borrowings and reported $10.7 of effective availability, after letters of credit, under its amended facility.
- The company received $74.7 net IPO proceeds. Convertible notes converted into common stock and subordinated notes were repaid; the balance sheet showed no convertible or subordinated notes at quarter-end.
Material changes versus prior comparable periods
- Q3 revenue increased 16%, led by 18% growth in product revenue. Management attributed growth to Asian and South American petrochemical sales, offshore oil projects, price increases, and a richer product mix. International revenue was about 68% of Q3 revenue.
- Year-to-date revenue increased 20%, while gross margin improved from 12% to 16%, reflecting improved manufacturing yields, throughput, purchasing efficiency, pricing, and product mix.
- Q3 operating loss narrowed to $2.4 from $4.7. Year-to-date operating loss was broadly unchanged at $13.4. Net loss for the nine months increased substantially, primarily because of fair-value accretion of convertible debt before its IPO conversion.
- Research-services revenue declined 20% year to date to $2.4; management cited fewer active government research contracts and limitations on eligibility for some federal awards.
Outlook, commentary, risks, and unusual items
- Capacity and spending: The company estimated the East Providence third production line would cost about $30 and add 10–11 million square feet of annual nameplate capacity, with completion expected in the first half of 2015. Management anticipated start-up expenses and significant capital spending; a second manufacturing plant was contemplated, subject to additional funding.
- Outlook: Management expected continued revenue growth, increased gross profit, and improving operating cash flows, but provided no specific numerical revenue or earnings guidance. It also cautioned that margins and Adjusted EBITDA may vary with product mix, capacity utilization, expansion costs, and stock compensation.
- Unusual IPO-related items: Nine-month net loss included $50.2 of interest expense, largely non-cash fair-value accretion associated with debt converted at the IPO. Management identified $38.8, or $4.43 per share, of IPO-related expense, including $5.6 of performance-based stock compensation and $33.2 of debt accretion to final conversion value. IPO proceeds also funded repayment of subordinated debt and the revolving-credit balance.
- Key risks: The business had a history of losses and expected future capital needs; operations depended on a single manufacturing facility pending expansion. Other risks included uncertain adoption and premium pricing of aerogel products, cyclical energy-industry demand, customer concentration, production and quality execution, raw-material supply and cost, international operations, and dependence on successful capacity expansion. The top ten direct customers represented 63% of nine-month revenue; one customer represented 18% of receivables.
- The company reported compliance with its credit-facility covenants, effective disclosure controls, no material legal proceedings, and no probable litigation loss requiring accrual or disclosure. It stated that it had no off-balance-sheet arrangements.
Important facts for investors to verify
- Whether the third production line is completed on schedule and within the estimated cost, and whether expected demand supports the added capacity.
- Whether operating cash flow remains positive after expansion spending and working-capital needs, and what financing will be required for a second plant.
- How much reported losses reflect recurring operations versus non-cash debt fair-value changes and IPO-related compensation.
- Whether customer concentration, large project timing, and reduced government research-contract activity affect revenue growth.
- The amended credit facility’s borrowing-base availability, covenant requirements, and restrictions on future financing.